What are the most common mistakes with 5-Amino-1MQ?
The most common 5-Amino-1MQ mistakes are treating it as a primary fat-loss agent rather than a metabolic adjunct; running long cycles without the safety data to back it; expecting GLP-class results. Most issues people run into come down to protocol and expectations, not the compound itself. Going in informed matters here because human evidence for 5-Amino-1MQ is limited.
Common 5-Amino-1MQ mistakes
- Treating it as a primary fat-loss agent rather than a metabolic adjunct
- Running long cycles without the safety data to back it
- Expecting GLP-class results
Bloodwork worth tracking
- Liver enzymes baseline + week 8 (limited data, monitor)
References
- Selective inhibitors of NNMT in obesity-related metabolic disease — Neelakantan H et al., Biochem Pharmacol, 2018
- Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome — Sun WD et al., Frontiers in Pharmacology, 2024
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on 5-Amino-1MQ
Last updated 2026-06-15.